Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

According to NAACP officials, Pastor Walter Womack, president of the Memphis Southern Christian Leadership Conference (SCLC), ...

The following is a summary of “Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer,” published in ...

Small cell lung cancer (SCLC) is one of the hardest types of cancer to treat and has often already spread by the time people are diagnosed. It mainly arises from neuroendocrine (NE) cells, which help ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Davis was the keynote speaker at the Roanoke Chapter of the Southern Christian Leadership Conference’s 28th annual luncheon organized to celebrate King’s life and legacy as the nation marks a ...

SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more ...

Immunotherapy has shown a 27% reduction in mortality for patients with limited-stage small cell lung cancer, based on Phase ...

“Receiving an Orphan Drug Designation for ZL-1310 recognizes its potential to treat patients with SCLC. These patients have an urgent need for innovative treatment options with improved ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...

Serplulimab was granted orphan drug designations by the FDA and the EC for the treatment of SCLC, and its bridging head-to-head trial in the United States to compare HANSIZHUANG to standard of ...